# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
BMO Capital analyst Etzer Darout reiterates Terns Pharma (NASDAQ:TERN) with a Outperform and raises the price target from $1...
Terns intends to use the net proceeds from the proposed offering, to fund research, clinical trials, development and manufactur...
JMP Securities analyst Silvan Tuerkcan maintains Terns Pharma (NASDAQ:TERN) with a Market Outperform and raises the price ta...
Terns Pharmaceuticals announced promising Phase 1 trial results for TERN-601, showing significant weight loss in obese and over...